Cardiac hypertrophy and failure are characterized by transcriptional reprogramming of gene expression. Adult cardiomyocytes in mice primarily express a-myosin heavy chain (a-MHC, also known as Myh6), whereas embryonic cardiomyocytes express b-MHC (also known as Myh7). Cardiac stress triggers adult hearts to undergo hypertrophy and a shift from a-MHC to fetal b-MHC expression. Here we show that Brg1, a chromatin-remodelling protein, has a critical role in regulating cardiac growth, differentiation and gene expression. In embryos, Brg1 promotes myocyte proliferation by maintaining Bmp10 and suppressing p57 kip2 expression. It preserves fetal cardiac differentiation by interacting with histone deacetylase (HDAC) and poly (ADP ribose) polymerase (PARP) to repress a-MHC and activate b-MHC. In adults, Brg1 (also known as Smarca4) is turned off in cardiomyocytes. It is reactivated by cardiac stresses and forms a complex with its embryonic partners, HDAC and PARP, to induce a pathological a-MHC to b-MHC shift. Preventing Brg1 re-expression decreases hypertrophy and reverses this MHC switch. BRG1 is activated in certain patients with hypertrophic cardiomyopathy, its level correlating with disease severity and MHC changes. Our studies show that Brg1 maintains cardiomyocytes in an embryonic state, and demonstrate an epigenetic mechanism by which three classes of chromatin-modifying factors-Brg1, HDAC and PARP-cooperate to control developmental and pathological gene expression.
Myosin heavy chain is the molecular motor in muscle cells, and two isoforms, a-MHC and b-MHC, are expressed specifically in mammalian hearts. a-MHC has higher ATPase activity than b-MHC, and the relative degree of a-MHC and b-MHC varies under different pathophysiological conditions 1 (Supplementary Fig. 1a ). The ato b-MHC ratio correlates directly with overall cardiac performance in animals [2] [3] [4] as well as in patients with cardiomyopathy and heart failure [5] [6] [7] [8] . MHC protein mutations also cause cardiac dysfunction in mice and humans 9, 10 . Pathological hypertrophy of adult hearts is associated with a-MHC downregulation and b-MHC induction 11 , which represents a return to a fetal state of MHC expression. However, hearts expressing a-MHC have a better outcome under stress conditions than those expressing mainly b-MHC [2] [3] [4] . Thus, strategies to control MHC expression represent an attractive approach for heart failure therapy 1, 12 .
Chromatin remodelling offers one such control to modulate gene expression. The Brg1/Brm-associated-factor (BAF) complex, consisting of 12 protein subunits, is a major type of ATP-dependent chromatin-remodelling complex in vertebrates 13 . Our studies show that Brg1, the essential ATPase subunit of the BAF complex 14 , interacts with two other classes of chromatin-modifying enzymes, HDAC 15 and PARP 16 , to regulate gene expression during cardiac growth, differentiation and hypertrophy in mice ( Supplementary Fig. 1b, c) . Both HDACs and PARP1 are therapeutic targets for cardiac hypertrophy, as pharmacological inhibition of their activities or genetic mutations of class I HDACs and PARP1 in mice reduce hypertrophy [17] [18] [19] [20] [21] [22] . The interaction of Brg1 with HDACs and PARP1, and its activation in certain patients with hypertrophic cardiomyopathy, indicate that Brg1/BAF may be a target for treating cardiac hypertrophy and failure.
Growth of Brg1-null myocardium
We used the Sm22a-cre transgene 23 to remove floxed alleles of Brg1 (Brg1 f ) 24 in the mouse myocardium (cardiomyocytes) by embryonic day (E)9.5 ( Supplementary Fig. 2a-c ). Sm22a-cre;Brg1 f/f embryos were grossly normal at E11.5, but died thereafter ( Supplementary  Fig. 2d , f). At E10.5 the heart had thin compact myocardium and failed to form an interventricular septum (Fig. 1a, b and Supplementary Fig. 3a-c ), although the trabeculation was normal 23 . At E11.5, the trabeculation, cardiac jelly and vasculature remained normal despite the thin myocardium and absent septum ( Supplementary  Figs 3d-f , 4a-f and Supplementary Text). Loss of compact myocardium could reduce cardiac output, causing embryonic lethality.
These embryos had almost no myocardial apoptosis (Supplementary Fig. 3g -l). The compact and septal primordial myocardium showed a marked decrease in cell proliferation at E10.5, whereas other heart layers were normal ( Fig. 1c-e and Supplementary Fig. 3m-o) . Therefore, Brg1 is required for cell proliferation to form the compact and septal myocardium.
To identify genes responsible for these defects, we used RNA in situ hybridization to survey crucial myocardial transcripts in E10-E11 Sm22a-cre;Brg1 f/f hearts, including Nkx2.5, Gata4, Mef2c, Tbx3, Tbx5, Cx43 (also known as Gja1), Irx1, Irx2, Nppa and Bmp10. We found no changes in these transcripts ( Supplementary Fig. 5 ) except for Bmp10, a key factor required for myocardial proliferation 25 . Bmp10 expression was nearly abolished in the compact myocardium of E10.5 Sm22acre;Brg1 f/f embryos ( Fig. 1f, g) . We next examined p57 kip2 , a cyclindependent kinase inhibitor, the expression of which is normally suppressed by Bmp10 25 . We found that the p57 kip2 level correlated inversely with normal cardiac cell proliferation ( Supplementary Fig. 6a ). Also, p57 kip2 appeared ectopically in E10.5 Sm22a-cre;Brg1 f/f myocardium ( Fig. 1h -j and Supplementary Fig. 6b ), correlating with Bmp10 reduction and termination of myocardial cell proliferation. The Bmp10/ p57 kip2 -mediated proliferation was confirmed when we rescued myocardial proliferation in Sm22a-cre;Brg1 f/f with recombinant BMP10 by whole embryo cultures 26 ( Supplementary Fig. 6c-e ).
We further used the Mef2c-cre line 27 to delete Brg1 in the right ventricular myocardium, leaving Brg1 intact in the endocardium and left ventricle ( Supplementary Fig. 7a, b ). Mef2c-cre;Brg1 f/f embryos had hypoplastic outflow tracts and right ventricles (Supplementary Fig. 7c -f, i, j). The Brg1-null right ventricle phenocopied the defects in Sm22a-cre;Brg1 f/f ventricles, namely Bmp10 downregulation, ectopic p57 kip2 expression and proliferation reduction (Supplementary Fig. 7c -h), whereas the Brg1-positive left ventricle was normal, demonstrating a primary and myocardially specific regulation of Bmp10/p57 kip2 by Brg1.
Differentiation of Brg1-null myocardium
We examined whether the early termination of proliferation in Sm22a-cre;Brg1 f/f myocardium was coupled with premature differentiation. We analysed the myofibril formation of E10.5 cardiomyocytes by a-actinin immunostaining and electron microscopy. Although control compact myocardial cells showed diffuse distribution of a-actinin, a component of Z-lines that demarcate sarcomeres, those of Sm22a-cre;Brg1 f/f began to show striated patterns ( Supplementary Fig. 9a, b ). Electron microscopy confirmed that Sm22a-cre;Brg1 f/f myocardium had consecutive sarcomeres whereas controls only had short myofibrils ( Fig. 2a, b ).
We then used quantitative PCR with reverse transcription (RT-PCR) to measure mRNA expression of the two MHC isoforms, a-MHC, which is mainly expressed by adult hearts, and b-MHC, which is expressed primarily by embryonic hearts. E10.5 and E11.5 Sm22a-cre;Brg1 f/f ventricles highly expressed a-MHC and downregulated b-MHC, thereby increasing the a-to b-MHC ratio by 7-12-fold ( Fig. 2c ). Together with myofibril analysis, these data indicate that Brg1-null myocardial cells are highly differentiated and thus support a role of Brg1 in maintaining myocardial cells in an embryonic state of differentiation.
To test if Brg1 directly regulates MHC expression, we examined Brg1 binding to MHC promoters. With sequence alignment (http:// www.dcode.org), we identified seven regions (a1-a7) in the mouse intergenic ,4 kilobase (kb) a-MHC promoter 28 that are evolutionarily conserved in mouse, rat and human ( Fig. 2d ). Chromatin immunoprecipitation (ChIP) assay using E11.5 hearts with J1 anti-Brg1 antibody 23 showed that of the seven regions, Brg1 was strongly associated with the proximal promoter (a1) of a-MHC ( Fig. 2e and Supplementary Text). In contrast with a-MHC, none of the four conserved regions in the 5 kb upstream promoter of Bmp10 was associated with Brg1 ( Supplementary Fig. 8a, b ). To test Brg1/BAF transcriptional activity, we cloned different regions of the a-MHC promoter into chromatinized episomal reporter pREP4 29 and then transfected the constructs into SW13 cells 23 , which lack Brg1 and Brm 30 (Supplementary Fig. 8d ). We found that restoring Brg1 expression caused an approximately 65-75% reduction in the a-MHC reporter activity, and the proximal promoter (a1) was critical for a-MHC repression ( Fig. 2f and Supplementary Fig. 8d ). These observations support a direct repression of a-MHC by Brg1.
Because HDACs are chromatin modifiers that mediate transcriptional repression 15 , we investigated whether Brg1 requires HDACs to repress a-MHC. Indeed, Brg1 failed to repress the a-MHC reporter in SW13 cells treated with trichostatin A, an HDAC inhibitor ( Fig. 2f ). Neither could HDAC repress the a-MHC reporter without Brg1 ( Fig. 2f ). HDAC proteins, including class I HDAC1, HDAC2 and HDAC3 and class II HDAC5, HDAC6 and HDAC9, were present in myocardial nuclei (Fig. 2j ), and Brg1 co-immunoprecipitated with HDAC1, HDAC2, HDAC3 and HDAC9 in E11.5 ventricles (data not shown; Fig. 2k ). These findings indicate that Brg1 and HDACs corepress a-MHC in the embryonic myocardium.
We also analysed the 5.5 kb b-MHC promoter 28 , where we identified five highly conserved regions (b1-b5 in Fig. 2g ). Brg1 was widely associated with four of the five regions by ChIP experiments (Fig. 2h ). Restoring Brg1 expression in SW13 cells activated b-MHC reporters ( Fig. 2i ). Deletional analysis of the b-MHC promoter showed that the proximal promoter (b1) was necessary for the Brg1-mediated b-MHC activation ( Fig. 2i and Supplementary Fig.  8e ). This activation of b-MHC did not require HDAC activity (Fig. 2i) ; however, HDAC is necessary for the basal activity of b-MHC, as HDAC inhibition resulted in a reduction of b-MHC promoter activity ( Fig. 2i ).
We then investigated whether HDAC inhibition in embryos causes premature a/b-MHC switches, as observed in Brg1-null myocardium. Indeed, trichostatin-A-treated cultured embryos significantly upregulated a-MHC, whereas b-MHC was downregulated ( Fig. 2l and Supplementary Fig. 9c, d Although trichostatin A causes MHC switches in embryos, HDAC inhibition did not reduce myocardial proliferation ( Supplementary  Fig. 9e-g) . Conversely, BMP10 rescued myocardial proliferation in Sm22a-cre;Brg1 f/f embryos, but did not influence a/b-MHC expression ( Supplementary Fig. 9h , i). Therefore, Brg1 governs two parallel pathways to independently control myocardial growth and differentiation in embryos.
Cardiac hypertrophy and MHC changes in adult hearts
We asked if Brg1 is also critical for cardiac growth and differentiation in stressed adult hearts. To bypass embryonic lethality, we used the doxycycline-inducible Tnnt2-rtTA;Tre-cre mouse line 31 to effect adult myocardial gene deletion. A 5-day doxycycline treatment was sufficient to activate a b-galactosidase reporter ( Supplementary Fig. 10a ). We surgically constricted the transverse aorta (transverse aortic constriction (TAC)) to pressure-overload the heart and induce cardiac hypertrophy in control and Tnnt2-rtTA;Tre-cre;Brg1 f/f littermates. The transgene and doxycycline alone did not cause hypertrophy ( Fig. 3a and Supplementary Fig. 10f ). Four weeks after surgery, the control and Tnnt2-rtta;Tre-cre;Brg1 f/f mice on a normal diet developed severe cardiac hypertrophy with increased cardiomyocyte size ( Fig. 3a and Supplementary Fig. 10b , c, f), ventricle:body-weight ratio (Supplementary Fig. 10f ), and cardiac fibrosis ( Supplementary Fig. 10g, i) . In contrast, doxycycline-treated Tnnt2-rtTA;Tre-cre;Brg1 f/f mice had only mild cardiac hypertrophy with a slight increase in cardiomyocyte size ( Fig. 3a and Supplementary Fig. 10d , e) and ventricle:body-weight ratio ( Supplementary Fig. 10f ), and without fibrosis ( Supplementary  Fig. 10h, j) . Overall, Brg1-null myocardium had a 63-73% reduction of cardiac hypertrophy. Thus, Brg1 is essential for the pressure-induced cardiac hypertrophy.
We next investigated whether Brg1 regulates MHC expression in hypertrophic hearts. Control hypertrophic hearts underwent canonical MHC changes, namely a-MHC downregulation and b-MHC upregulation (Fig. 3b ). In contrast, doxycycline-treated Tnnt2-rtTA;Tre-cre;Brg1 f/f mice showed a 2.1-fold increase in a-MHC and a 51% reduction in b-MHC (Fig. 3b) . Consequently, the pressurestressed Brg1-null myocardium showed a 4.4-fold increase in a-MHC expression and an 87% decrease in b-MHC expression compared with the control myocardium (Fig. 3c ). This reversal of MHC was not caused by reduced hypertrophy, which could only lessen but not reverse canonical MHC changes. Therefore, Brg1 is critical for the a/b-MHC switch in hypertrophic hearts.
Although Brg1 is highly expressed in embryonic hearts 23 , it is turned off in adult myocardium with some expression in endothelial or interstitial cells (Fig. 4a ). Brg1 became detectable in cardiomyocytes within 7 days after TAC by immunostaining (Fig. 4b ) confirmed by western blot (Fig. 4d ), although it remained absent in Tnnt2-rtTA;Tre-cre;Brg1 f/f myocardium (Fig. 4c ). Also, Brg1 mRNA increased by 1.8 fold within 2 weeks after TAC (Fig. 4e) , indicating that Brg1 reactivation by stress signals is essential for the hypertrophic process.
We then determined if reactivated Brg1 controls MHC expression through the direct binding of MHC promoters. ChIP analysis of TACtreated hearts showed Brg1 was highly enriched in the proximal promoters of both a-MHC and b-MHC, but not Bmp10 ( Fig. 4f and Supplementary Fig. 8a, c) . Furthermore, Brg1 binding to MHC promoters was detectable only in TAC-treated, but not sham-operated, hearts ( Supplementary Fig. 10k ), consistent with Brg1 reactivation by pressure overload. The binding pattern was similar to that in embryonic hearts ( Fig. 2e, h) , indicating a common mechanism underlying the Brg1mediated MHC control in embryonic and hypertrophic hearts.
MHC regulation by Brg1, HDAC and PARP
Besides HDACs [18] [19] [20] , PARP1 is the only other chromatin-modifying enzyme 16 known to regulate cardiac hypertrophy 17, 22 . However, it is unknown whether PARP1 binds to MHC promoters. ChIP analysis of TAC-treated hearts showed that PARP1 bound to the proximal promoters of a-MHC and b-MHC, but not Bmp10, a pattern similar to that of Brg1 ( Fig. 4f and Supplementary Fig. 11a ). Like Brg1, PARP1 binding occurred only in TAC-treated, but not sham-operated, hearts (data not shown). Furthermore, inhibiting PARP1 activity using PJ-34 32 reduced both Brg1-mediated a-MHC repression and b-MHC activation in reporter assays in SW13 cells, indicating that Brg1 and PARP1 cooperate to regulate MHC (Fig. 4g, h) . Indeed, PARP1 and Brg1 co-immunoprecipitated in both TAC-treated hearts and E11.5 hearts (Fig. 4i, j) . Embryos cultured with PJ-34 had normal myocardial proliferation, but showed a/b-MHC switches characteristic of Brg1-null myocardium ( Fig. 4k and Supplementary Fig. 11b ). Immunostaining and ChIP analyses of E11.5 hearts showed that PARP1 was present in myocardial nuclei and bound to the proximal promoters of a-and b-MHC but not Bmp10, a pattern similar to that of Brg1 ( Fig. 4l and Supplementary Fig. 11c, d) . These findings indicate that Brg1 complexes with PARP1 to regulate MHC in embryonic and stressed adult hearts.
Brg1 and PARP1 co-immunoprecipitated with HDAC1, HDAC2 or HDAC9 in E11.5 and stressed adult hearts (Figs 2k, 4i, j and Supplementary Fig. 11e ). We asked whether HDACs are present on MHC promoters. Using ChIP with two cross-linking steps 33 in TACtreated hearts, we found that HDAC2 and HDAC9 were enriched in the a-MHC promoter but bound modestly to the b-MHC promoter ( Fig. 4m and Supplementary Fig. 11f ), suggesting direct a-MHC and indirect b-MHC regulation by HDACs. Together with reporter assays (Figs 2f, i, 4g, h) , these biochemical studies indicate that Brg1, PARP and HDAC physically form a chromatin-remodelling complex on the a-MHC promoter to repress a-MHC, whereas Brg1 complexes with PARP on the b-MHC promoter to activate b-MHC.
Implication for human cardiomyopathy
To investigate if BRG1 is activated in human hypertrophic hearts, we studied patients with hypertrophic cardiomyopathy of unknown aetiology, who required surgical myectomy 34 to relieve cardiac obstruction caused by prominent ventricular or septal hypertrophy ( Supplementary Fig. 12a ). The severity of hypertrophic cardiomyopathy was measured by the maximal thickness of the interventricular septum during diastole (IVSd). IVSd in hypertrophic cardiomyopathy patients was 2.02-fold that of the control group ( Supplementary  Fig. 12b, c) . Quantitative RT-PCR analyses showed that hearts with hypertrophic cardiomyopathy had a 48-fold reduction of a-MHC, a 5.5-fold increase of b-MHC and a twofold increase of BRG1 expression (Fig. 5a) . The loss of a-MHC, gain of b-MHC and activation of BRG1 resembled the changes observed in mice with hypertrophy, indicating that BRG1 has a similar role in human disease. Consistent with this notion, the IVSd and b-MHC:a-MHC ratio correlated well with the BRG1 level in control and hypertrophic cardiomyopathy subjects, with sigmoidal regression curves inflecting at 1.50-fold and 1.45-fold of BRG1, respectively (Fig. 5b, c and Supplementary Fig. 12d, e ). At the inflection point of 1.50-fold BRG1, IVSd equals 1.54 cm, coinciding with a clinical criterion (IVSd . 1.50 cm) in the diagnosis of hypertrophic cardiomyopathy 35 . We therefore speculate that a 50% increase in BRG1 may be a threshold for disease development in certain patients.
Discussion
Brg1/BAF may have regenerative and therapeutic implications given its newly identified roles in both embryonic and adult cardiomyocytes. Similar mechanisms are directed by Brg1 to control cardiac growth, differentiation and gene expression under developmental and pathological conditions ( Supplementary Fig. 1b, c) . The stressdependent assembly of a developmental complex to modify chromatins in adult hearts provides a molecular explanation for fetal gene activation in the diseased adult myocardium. HDAC, PARP and now Brg1/BAF are the only classes of chromatin-modifying factors known to regulate cardiac hypertrophy. Cardiac stresses activate Brg1, which then assembles a BAF/HDAC/PARP chromatin complex on MHC promoters (Fig. 5d ), where they may interact with transcription factors such as TR, TEF1, MEF2, SRF, GATA4 and NFAT 36, 37 to control MHC expression. The induction of Brg1 by hypertrophic stimuli suggests that chromatin may ultimately be where all the stress-response signals converge for the regulation of MHC genes, a critical step in the myopathic process. Normalized luciferase activity
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IgG IP: Anti-HDAC2 Brg1/BAF, aside from thyroid hormone receptors 36 , provides the only known direct mechanism to antithetically regulate a-MHC and b-MHC. This opposite MHC regulation may underlie the on-off, rather than graded, switching of MHC in individual cardiomyocytes of hypertrophic hearts 28 . Exactly how HDACs and PARPs contribute to this BAF-mediated process awaits further investigations. HDACs and PARPs may covalently modify histones and thereby help anchor BAF to certain sites of MHC promoters. BAF proteins may also be modified through acetylation/deacetylation or poly-ADP-ribosylation by HDACs and PARPs. Such modifications may decide the composition of the BAF complex and how BAF interacts with chromatin as well as with other MHC regulators such as miR-208 1 . Elucidating these issues will help to determine how the chromatin and target specificities of BAF may be established by its possible combinatorial assembly with the large families of 17 PARP 16 and 18 HDAC 15 proteins.
METHODS SUMMARY
Sm22a-cre, Brg1 f/f , Mef2c-cre, R26R and Tnnt2-rtTA;Tre-cre mice have been previously described 23, 24, 27, 31, 38 . Immunostaining, RNA in situ hybridization, quantitative RT-PCR and whole embryo culture were performed as described 23, 26 . TAC was modified from previous descriptions 20 . The pressure load caused by TAC was verified by the pressure gradient across the aortic constriction measured by echocardiography. Curve modelling was performed with the Levenburg-Marquardt nonlinear regression method and XLfit software.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. approach was used, and 3-8 g of tissue was removed from the proximal septum after retraction of the mitral valve. Normal tissue was acquired from heart transplant donors where the heart was not used for transplantation or by biopsy immediately following implantation. Heart tissue was flash frozen in liquid nitrogen immediately and stored at 280 uC. For analysis, the tissues were thawed, RNA was extracted and subjected to quantitative RT-PCR analysis. The use of human tissues is in compliance with Stanford University regulation. Construction of regression curves and derivation of equations. The regression curve, equation and r-square (r 2 ) for Fig. 5b , c are derived using the Levenburg-Marquardt nonlinear regression method and a statistics/curve modelling software (XLfit, 2005) . Different curve models ranging from linear, polynomial, exponential/log, power series, hyperbolic and sigmoidal curves were tested. The curves that fit best with the data points based on r 2 and F-tests are shown in Fig. 5 . The mathematical derivations of the inflection points are described in Supplementary Fig. 12d , e. 39. Chang, C. P., Chen, L. & Crabtree, G. R. Sonographic staging of the developmental status of mouse embryos in utero. Genesis 36, 7-11 (2003) .
